Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease

Clinical Neuropharmacology

Volumn 35, Issue 1, 2012, Pages 6-14

  Nyholm, Dag ^a   Johansson, Anders ^a   Aquilonius, Sten Magnus ^a   Hellquist, Elisabeth ^a   Lennernäs, Hans ^a   Askmark, Håkan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

dyskinesias; intestinal infusion; levodopa carbidopa; Parkinson disease; pharmacokinetics

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; ARTICLE; BRADYKINESIA; CHOREA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DUODENUM; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MOTOR PERFORMANCE; PARKINSON DISEASE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; DUODENUM; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; VIDEO RECORDING;

EID: 84855824156     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31823b1ffd     Document Type: Article

References (32)

1. Contin M, Riva R, Martinelli P, et al. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study. Clin Neuropharmacol 1997;20(5):409-418. (Pubitemid 27424331)
2. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008;4(2):193-203. (Pubitemid 351308417)
3. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22(10):1379-1389; quiz 1523. (Pubitemid 47280623)
4. Krack P, Pollak P, Limousin P, et al. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999;122(Pt 6):1133-1146. (Pubitemid 29533128)
5. Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9(1):2-12. (Pubitemid 24022609)
6. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl):S13-S17. (Pubitemid 47444538)
7. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6(10):1403-1411. (Pubitemid 44696265)
8. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
9. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9(4):390-394. (Pubitemid 24238365)
10. Zackrisson T, Holmberg B, Johnels B, et al. A new automated implementation of the Posturo-Locomotion-Manual (PLM) method for movement analysis in patients with Parkinson's disease. Acta Neurol Scand 2011;123(4):274-279.
11. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31(2):63-73. (Pubitemid 351489331)
12. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26(3):156-163. (Pubitemid 36676295)
13. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-223.
14. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord 2010;25(9):1131-1142.
15. Tedroff J, Aquilonius SM, Hartvig P, et al. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand 1992;85(2):95-102.
16. Hung SW, Adeli GM, Arenovich T, et al. Patient perception of dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;81(10):1112-1115.
17. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22(8):1145-1149. (Pubitemid 47067225)
18. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31(3):151-166. (Pubitemid 351787111)
19. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190-199. (Pubitemid 40361122)
20. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010;(7):CD007166.
21. Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(1):57-61.
22. Schrag A, Hovris A, Morley D, et al. Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 2003;18(11):1250-1256. (Pubitemid 38263307)
23. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12(12):956-963. (Pubitemid 41820050)
24. Bachmann CG, Zapf A, Brunner E, et al. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. Eur J Neurol 2009;16(8):895-901.
25. Goetz CG, Leurgans S, Hinson VK, et al. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord 2008;23(10): 1479-1482.
26. Isacson D, Bingefors K, Kristiansen IS, et al. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118(6): 379-386.
27. Adamiak U, Kaldonska M, Klodowska-Duda G, et al. Pharmacokinetic- pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 2010;33(3):135-141.
28. Westin J, Nyholm D, Groth T, et al. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2006;12(8):509-513. (Pubitemid 44793109)
29. Gunzler SA, Pavel M, Koudelka C, et al. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials. Clin Neuropharmacol 2009;32(2):97-102.
30. Sage JI, Mark MH, McHale DM, et al. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea. Ann Neurol 1991;29(6):623-628.
31. McHale DM, Sage JI, Sonsalla PK, et al. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990;13(2):164-170. (Pubitemid 20109360)
32. Westin J, Nyholm D, Pålhagen S, et al. A pharmacokinetic- pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol 2011;34(2):61-65.